Genentech Oncology
Investigational Therapies
These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.
Showing 87 out of 87 results
Phase III
Breast
Gastrointestinal
Hematology
Lung
Phase II
Gastrointestinal
Hematology
Lung
Melanoma
Solid Tumor
Phase I
Brain
Breast
Gastrointestinal
Genitourinary
Gynecologic
Head Neck
Hematology
Lung
Melanoma
Solid Tumor
aDeveloped in collaboration with Array Biopharma.bDeveloped in collaboration with Exelixis. cJoint project with AbbVie. dManaged by Repare Therapeutics. eDeveloped in collaboration with Immunocore. fDeveloped in collaboration with Relay Therapeutics. gDeveloped in collaboration with Chugai. hDeveloped in collaboration with Xencor. iManaged by Poseida Therapeutics.
Current as of February 2, 2023. The trial information is taken from ClinicalTrials.gov.
-
-
Roche. 2022 Q4 results. February 2, 2023. Accessed February 15, 2023. https://assets.cwp.roche.com/f/126832/x/5738a7538b/irp230202.pdf
Roche. 2022 Q4 results. February 2, 2023. Accessed February 15, 2023. https://assets.cwp.roche.com/f/126832/x/5738a7538b/irp230202.pdf
-
-